{
  "material_id": "pfa-05",
  "slug": "pfa-safety-serious-complications",
  "language": "en",
  "canonical_url": "https://hub.bookimed.com/pulsed-field-ablation/pfa-safety-serious-complications/",
  "title": "PFA safety: serious complications and what the numbers mean",
  "hero": {
    "text": "PFA may limit injury to nearby tissues, but it is still an invasive catheter procedure. In MANIFEST-17K, major complications were reported in 173 of 17,642 patients—about one in a hundred. No reported injury in a particular category does not mean that its future risk is zero.",
    "fact_refs": [
      "fact:pfa:exp:manifest",
      "fact:pfa:compose:risks"
    ],
    "source_refs": [
      "source:40efbaf00763",
      "source:70d0511f82f6"
    ],
    "id": "hero-answer"
  },
  "summary": {
    "text": "Separate three questions: serious events linked to the device or procedure, specific rare injuries, and the broader symptoms or side effects you may experience. A trial’s safety endpoint does not count every possible adverse experience, and a registry percentage is not your personal risk.",
    "fact_refs": [
      "fact:pfa:c4",
      "fact:pfa:exp:manifest",
      "fact:pfa:compose:risks"
    ],
    "source_refs": [
      "source:c2b1a75334d9",
      "source:40efbaf00763",
      "source:70d0511f82f6"
    ],
    "id": "summary"
  },
  "takeaways": [
    {
      "text": "Noninferiority in ADVENT did not establish superior overall safety.",
      "fact_refs": [
        "fact:pfa:c4"
      ],
      "source_refs": [
        "source:c2b1a75334d9"
      ],
      "label": "A comparison, not a guarantee",
      "id": "takeaway-0"
    },
    {
      "text": "MANIFEST-17K recorded rare stroke, death, coronary spasm and kidney injury.",
      "fact_refs": [
        "fact:pfa:exp:manifest"
      ],
      "source_refs": [
        "source:40efbaf00763"
      ],
      "label": "Rare is not impossible",
      "id": "takeaway-1"
    },
    {
      "text": "Get a written follow-up and urgent-contact plan before discharge.",
      "fact_refs": [
        "fact:pfa:compose:red-flags"
      ],
      "source_refs": [
        "source:70d0511f82f6"
      ],
      "label": "Know your next step",
      "id": "takeaway-2"
    }
  ],
  "sections": [
    {
      "id": "scope",
      "heading": "Tissue sparing does not remove procedural risk",
      "paragraphs": [
        {
          "text": "PFA uses electrical pulses rather than heat or freezing. Its tissue selectivity can limit damage near the heart, including the oesophagus and phrenic nerve, and reduce pulmonary-vein narrowing. But a catheter still travels through a groin vein to the heart. Bleeding or vascular injury, fluid around the heart and stroke remain relevant concerns.",
          "fact_refs": [
            "fact:pfa:compose:journey",
            "fact:pfa:compose:risks",
            "fact:pfa:exp:manifest"
          ],
          "source_refs": [
            "source:70d0511f82f6",
            "source:40efbaf00763"
          ],
          "id": "scope-paragraphs-0"
        },
        {
          "text": "Bruising, palpitations, fatigue, breathlessness, slow heart rate and reversible phrenic-nerve stunning are among the possible effects described in patient information. They are not interchangeable with a study’s predefined serious-event composite. Do not use the serious-event percentage as the probability of having any symptom after treatment.",
          "fact_refs": [
            "fact:pfa:compose:risks",
            "fact:pfa:c4"
          ],
          "source_refs": [
            "source:70d0511f82f6",
            "source:c2b1a75334d9"
          ],
          "id": "scope-paragraphs-1"
        }
      ],
      "provider_slots": []
    },
    {
      "id": "device-population",
      "heading": "Which device and AF pattern do these findings concern?",
      "paragraphs": [
        {
          "text": "The platform and AF pattern matter. The US FDA FARAWAVE indication dated January 12, 2026 covers pulmonary-vein isolation for drug-refractory, recurrent, symptomatic paroxysmal AF, and pulmonary-vein plus posterior-wall isolation for drug-refractory, symptomatic persistent AF with episodes lasting less than one year. ADVENT’s randomized safety comparison concerned FARAPULSE in paroxysmal AF; it does not establish the same comparison in persistent AF or with every other PFA platform. The device-specific notices below have their own product and batch limits, separate from these study and indication limits.",
          "fact_refs": [
            "fact:pfa:compose:fda-label",
            "fact:pfa:c2",
            "fact:pfa:c4",
            "fact:pfa:c12",
            "fact:pfa:c13",
            "fact:pfa:c14"
          ],
          "source_refs": [
            "source:64edc5867c38",
            "source:c2b1a75334d9",
            "source:d1efd743478e"
          ],
          "id": "device-population-paragraphs-0"
        }
      ],
      "provider_slots": []
    },
    {
      "id": "trial",
      "heading": "ADVENT: the randomized serious-event comparison",
      "paragraphs": [
        {
          "text": "ADVENT studied drug-refractory paroxysmal AF using FARAPULSE versus pooled thermal ablation (radiofrequency or cryoballoon). Across its one-year assessment, the primary safety endpoint covered acute and chronic serious events related to the device or procedure—not all illnesses, symptoms or complications from any cause. The protocol lists safety windows of seven days and twelve months.",
          "fact_refs": [
            "fact:pfa:c2",
            "fact:pfa:c4",
            "fact:pfa:c12",
            "fact:pfa:c13",
            "fact:pfa:c14"
          ],
          "source_refs": [
            "source:c2b1a75334d9",
            "source:d1efd743478e"
          ],
          "id": "trial-paragraphs-0"
        },
        {
          "text": "Events occurred in six PFA patients and four thermal patients. The reported estimated incidences were 2.1% and 1.5%, respectively; these estimates should not be presented as simple fractions of the 305 and 302 randomized patients. The difference was 0.6 percentage points, with a 95% Bayesian credible interval from −1.5 to 2.8 percentage points. The interval allows differences in either direction.",
          "fact_refs": [
            "fact:pfa:c4"
          ],
          "source_refs": [
            "source:c2b1a75334d9"
          ],
          "id": "trial-paragraphs-1"
        },
        {
          "text": "In patient terms, the reported estimates are about two versus one to two people in a hundred for this specific serious-event endpoint. ADVENT met its noninferiority criterion; it did not prove that PFA was safer overall, that the methods were identical, or that rare injuries could not occur. It was not a direct demonstration of superiority over each thermal technology.",
          "fact_refs": [
            "fact:pfa:c4",
            "fact:pfa:c5"
          ],
          "source_refs": [
            "source:c2b1a75334d9"
          ],
          "id": "trial-paragraphs-2"
        }
      ],
      "provider_slots": []
    },
    {
      "id": "registry",
      "heading": "MANIFEST-17K: the denominator behind the reassurance",
      "paragraphs": [
        {
          "text": "This post-approval registry collected data from 106 of 116 centres using a pentaspline PFA catheter. Its 17,642 patients included both paroxysmal and persistent AF. Major complications were reported in 173 patients, approximately 1%. This is a registry of reported complications, not a randomized comparison or a lifetime risk estimate.",
          "fact_refs": [
            "fact:pfa:exp:manifest"
          ],
          "source_refs": [
            "source:40efbaf00763"
          ],
          "id": "registry-paragraphs-0"
        }
      ],
      "table": {
        "caption": "Reported MANIFEST-17K events: the same 17,642-patient denominator throughout",
        "columns": [
          "Event",
          "Reported count",
          "Reported percentage",
          "Approximate patient interpretation"
        ],
        "rows": [
          {
            "cells": [
              "Major complications",
              "173 of 17,642",
              "about 1%",
              "About 10 in 1,000 patients overall; do not add the rows below."
            ],
            "fact_refs": [
              "fact:pfa:exp:manifest"
            ],
            "source_refs": [
              "source:40efbaf00763"
            ],
            "id": "registry-row-0"
          },
          {
            "cells": [
              "Pericardial tamponade",
              "63 of 17,642",
              "0.36%",
              "Fluid or bleeding compressing the heart; about 4 in 1,000."
            ],
            "fact_refs": [
              "fact:pfa:exp:manifest"
            ],
            "source_refs": [
              "source:40efbaf00763"
            ],
            "id": "registry-row-1"
          },
          {
            "cells": [
              "Vascular events",
              "53 of 17,642",
              "0.30%",
              "Blood-vessel complications; about 3 in 1,000."
            ],
            "fact_refs": [
              "fact:pfa:exp:manifest"
            ],
            "source_refs": [
              "source:40efbaf00763"
            ],
            "id": "registry-row-2"
          },
          {
            "cells": [
              "Stroke",
              "22 of 17,642",
              "0.12%",
              "About 1 in 1,000."
            ],
            "fact_refs": [
              "fact:pfa:exp:manifest"
            ],
            "source_refs": [
              "source:40efbaf00763"
            ],
            "id": "registry-row-3"
          },
          {
            "cells": [
              "Death",
              "5 of 17,642",
              "0.03%",
              "About 3 in 10,000."
            ],
            "fact_refs": [
              "fact:pfa:exp:manifest"
            ],
            "source_refs": [
              "source:40efbaf00763"
            ],
            "id": "registry-row-4"
          },
          {
            "cells": [
              "Coronary arterial spasm",
              "25 of 17,642",
              "0.14%",
              "Spasm of a heart artery; about 1 to 2 in 1,000."
            ],
            "fact_refs": [
              "fact:pfa:exp:manifest"
            ],
            "source_refs": [
              "source:40efbaf00763"
            ],
            "id": "registry-row-5"
          },
          {
            "cells": [
              "Haemolysis-related kidney failure requiring dialysis",
              "5 of 17,642",
              "0.03%",
              "Red-cell breakdown linked to acute kidney failure; about 3 in 10,000."
            ],
            "fact_refs": [
              "fact:pfa:exp:manifest"
            ],
            "source_refs": [
              "source:40efbaf00763"
            ],
            "id": "registry-row-6"
          }
        ]
      },
      "provider_slots": []
    },
    {
      "id": "risk-meaning",
      "heading": "Tamponade and haemolysis in plain language",
      "paragraphs": [
        {
          "text": "Tamponade means blood or other fluid builds up in the sac around the heart and presses on it, so the heart cannot fill and pump properly. It is a medical emergency that may require drainage with a needle or surgery. Fluid around the heart (an effusion) does not always cause tamponade.",
          "fact_refs": [
            "fact:pfa:safety:tamponade"
          ],
          "source_refs": [
            "source:pfa:tamponade"
          ],
          "id": "risk-meaning-paragraphs-0"
        },
        {
          "text": "Haemolysis means the breakdown of red blood cells. When it happens inside blood vessels, parts of the destroyed cells circulate in the blood. MANIFEST-17K reported five cases of haemolysis-related acute kidney failure requiring dialysis among 17,642 patients. That is a specific severe kidney outcome, not the frequency of all red-cell breakdown after PFA.",
          "fact_refs": [
            "fact:pfa:safety:hemolysis",
            "fact:pfa:exp:manifest"
          ],
          "source_refs": [
            "source:pfa:hemolysis",
            "source:40efbaf00763"
          ],
          "id": "risk-meaning-paragraphs-1"
        }
      ],
      "provider_slots": []
    },
    {
      "id": "zero",
      "heading": "What “none reported” actually means",
      "paragraphs": [
        {
          "text": "Among the 17,642 patients, no oesophageal complications, pulmonary-vein stenosis or persistent phrenic palsy were reported. Transient phrenic palsy did occur: 11 cases (0.06%). Persistent and temporary nerve injury must not be collapsed into a claim of “no nerve injury.”",
          "fact_refs": [
            "fact:pfa:exp:manifest"
          ],
          "source_refs": [
            "source:40efbaf00763"
          ],
          "id": "zero-paragraphs-0"
        },
        {
          "text": "These observations are reassuring about collateral-tissue injury in this dataset. They cannot establish zero future risk. Reporting, surveillance and event definitions influence what a registry captures. Its results should not be transferred unchanged to another PFA platform or to your individual circumstances. Do not compare its approximately 1% major-complication figure directly with ADVENT’s 2.1% estimate: populations, event definitions and observation methods differ.",
          "fact_refs": [
            "fact:pfa:exp:manifest",
            "fact:pfa:c4"
          ],
          "source_refs": [
            "source:40efbaf00763",
            "source:c2b1a75334d9"
          ],
          "id": "zero-paragraphs-1"
        }
      ],
      "provider_slots": []
    },
    {
      "id": "device-notices",
      "heading": "Two device-specific notices—not a recall of all PFA",
      "paragraphs": [
        {
          "text": "United States: FDA Class II recall Z-2278-2025 covers specified FARAWAVE 1.0 ablation catheters, product M004PF41M401 (UDI-DI 00191506043148). The firm initiated it on June 25, 2025; FDA posted it on August 8, 2025. It lists 445 units distributed nationwide. Equipment used to manufacture the affected units may have caused cracks in electrode bands at the catheter’s tip. The instruction is not to use affected units: facilities must remove them from stock, segregate and return them.",
          "fact_refs": [
            "fact:pfa:safety:fda-z2278"
          ],
          "source_refs": [
            "source:pfa:fda-z2278"
          ],
          "id": "device-notices-paragraphs-0"
        },
        {
          "text": "The FDA record lists these affected batch numbers: 36543581, 36543644, 36543646, 36568553, 36572565, 36572568, 36572571, 36572576, 36578308, 36578314, 36579110, 36598352, 36598809, 36599402, 36600406, 36600543, 36600544, 36600545, 36600578. This is a batch-specific removal, not a finding that every FARAWAVE catheter or every PFA treatment is recalled.",
          "fact_refs": [
            "fact:pfa:safety:fda-z2278"
          ],
          "source_refs": [
            "source:pfa:fda-z2278"
          ],
          "id": "device-notices-paragraphs-1"
        },
        {
          "text": "Canada: Health Canada notice RA-82221 is a Type II recall for the FARADRIVE™ Steerable Sheath, model M004PF21M402. The recall date is June 11, 2026; the notice was published June 19, 2026. It identifies more than 50 lots and directs users to the manufacturer for the lot details. This notice concerns a forthcoming Instructions for Use update and the known air-embolism risk during left-atrial procedures involving transseptal sheaths and catheter exchanges. It reports that the sheath continues to perform within established expectations and directs users to contact the manufacturer for more information. It does not instruct removal of all PFA systems.",
          "fact_refs": [
            "fact:pfa:safety:hc-ra82221"
          ],
          "source_refs": [
            "source:pfa:hc-ra82221"
          ],
          "id": "device-notices-paragraphs-2"
        },
        {
          "text": "For a planned procedure, the treatment centre needs to match its exact catheter or sheath and lot to the applicable notice and follow the manufacturer’s instructions, including air-embolism precautions. For a past procedure, the centre can check its device record if there is concern about an affected batch. These notices identify product-specific actions; their unit counts and reports are not estimates of your chance of a PFA complication.",
          "fact_refs": [
            "fact:pfa:safety:fda-z2278",
            "fact:pfa:safety:hc-ra82221"
          ],
          "source_refs": [
            "source:pfa:fda-z2278",
            "source:pfa:hc-ra82221"
          ],
          "id": "device-notices-paragraphs-3"
        }
      ],
      "provider_slots": []
    },
    {
      "id": "action",
      "heading": "Before treatment and after discharge",
      "paragraphs": [
        {
          "text": "Before treatment, obtain a written plan identifying the device and treatment areas, how complications would be managed and the follow-up contact. The device-specific actions above belong to the clinical team’s equipment checks. An individual consent discussion must also cover the catheter-procedure risks described here; tissue selectivity does not eliminate bleeding, tamponade or stroke.",
          "fact_refs": [
            "fact:pfa:safety:fda-z2278",
            "fact:pfa:safety:hc-ra82221",
            "fact:pfa:exp:manifest"
          ],
          "source_refs": [
            "source:pfa:fda-z2278",
            "source:pfa:hc-ra82221",
            "source:40efbaf00763"
          ],
          "id": "action-paragraphs-0"
        },
        {
          "text": "Get written instructions for medicines, rhythm checks and who to contact after you leave. Do not stop or alter prescribed treatment on the strength of these study results. Cleveland Clinic describes follow-up at one, three and six months, then every six months; that is an institutional example, not a universal schedule.",
          "fact_refs": [
            "fact:pfa:compose:cleveland-followup"
          ],
          "source_refs": [
            "source:70d0511f82f6"
          ],
          "id": "action-paragraphs-1"
        },
        {
          "text": "Arm weakness or face drooping can be stroke symptoms: call your local emergency number immediately. After the procedure, contact your provider for groin-wound bleeding, swelling or a lump, dizziness, leg pain or numbness, chest pain or new AF symptoms. Follow the discharge team’s instructions; an online enquiry is not an emergency route.",
          "fact_refs": [
            "fact:pfa:compose:red-flags"
          ],
          "source_refs": [
            "source:70d0511f82f6"
          ],
          "id": "action-paragraphs-2"
        }
      ],
      "provider_slots": []
    },
    {
      "id": "coordination",
      "heading": "What Bookimed can help with",
      "paragraphs": [
        {
          "text": "Bookimed coordinators can help match hospitals and doctors, request individual treatment programmes and arrange a second medical opinion. Bookimed does not provide medical advice. These services do not guarantee PFA eligibility, a named clinician, availability at a particular clinic or a treatment price.",
          "fact_refs": [
            "fact:pfa:compose:bookimed-coordination"
          ],
          "source_refs": [
            "source:pfa:bookimed-coordinator"
          ],
          "id": "coordination-paragraphs-0"
        }
      ],
      "provider_slots": []
    }
  ],
  "providers": {},
  "sources": [
    {
      "id": "source:c2b1a75334d9",
      "url": "https://pubmed.ncbi.nlm.nih.gov/37634148/",
      "title": "ADVENT (2023): randomized PFA versus pooled thermal ablation — primary abstract"
    },
    {
      "id": "source:40efbaf00763",
      "url": "https://pubmed.ncbi.nlm.nih.gov/38977913/",
      "title": "MANIFEST-17K (2024): post-approval safety registry"
    },
    {
      "id": "source:70d0511f82f6",
      "url": "https://my.clevelandclinic.org/health/treatments/pulsed-field-ablation",
      "title": "Cleveland Clinic: pulsed field ablation, recovery and precautions"
    },
    {
      "id": "source:64edc5867c38",
      "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P230030S012",
      "title": "FDA FARAPULSE supplement P230030S012 (January 12, 2026): approved indications"
    },
    {
      "id": "source:d1efd743478e",
      "url": "https://clinicaltrials.gov/api/v2/studies/NCT04612244",
      "title": "ClinicalTrials.gov NCT04612244: ADVENT protocol and reported results"
    },
    {
      "id": "source:pfa:tamponade",
      "url": "https://my.clevelandclinic.org/health/diseases/21906-cardiac-tamponade",
      "title": "Cleveland Clinic: cardiac tamponade—pressure around the heart"
    },
    {
      "id": "source:pfa:hemolysis",
      "url": "https://my.clevelandclinic.org/health/diseases/24108-hemolysis",
      "title": "Cleveland Clinic: haemolysis—red blood cell destruction"
    },
    {
      "id": "source:pfa:fda-z2278",
      "url": "https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRES/res.cfm?id=214843",
      "title": "FDA: FARAWAVE 1.0 Class II recall Z-2278-2025"
    },
    {
      "id": "source:pfa:hc-ra82221",
      "url": "https://recalls-rappels.canada.ca/en/alert-recall/faradrivetm-steerable-sheath",
      "title": "Health Canada: FARADRIVE sheath notice RA-82221 (June 2026)"
    },
    {
      "id": "source:pfa:bookimed-coordinator",
      "url": "https://us-uk.bookimed.com/page/bookimed-medical-coordinator",
      "title": "Bookimed medical coordinators: services and limits"
    }
  ],
  "cta": {
    "heading": "Discuss an individual assessment",
    "body": "Ask an electrophysiologist to check your AF pattern, proposed device and treatment plan. You can send a request through Bookimed; this is not a booking confirmation, medical advice or a guarantee of PFA eligibility at any named clinic.",
    "label": "Request assessment support",
    "sticky_text": "Check your AF pattern and treatment options",
    "url": "https://us-uk.bookimed.com/order-create/question-about-medical-entity/?illnessId=150&type=messenger-priority&lref=eyJwYWdlVVJMIjoiaHR0cHM6Ly9odWIuYm9va2ltZWQuY29tL3B1bHNlZC1maWVsZC1hYmxhdGlvbi9wZmEtc2FmZXR5LXNlcmlvdXMtY29tcGxpY2F0aW9ucy8iLCJ0b3BpYyI6IlBGQSBzYWZldHk6IHNlcmlvdXMgY29tcGxpY2F0aW9ucyBhbmQgd2hhdCB0aGUgbnVtYmVycyBtZWFuIiwiaW50ZW50IjoiSW5kaXZpZHVhbCBBRiBhc3Nlc3NtZW50OyBjbGFyaWZ5IGRldmljZSwgZWxpZ2liaWxpdHkgYW5kIHJpc2tzIn0%3D&utm_source=bookimed_hub&utm_medium=referral&utm_campaign=pfa_learning&button=pfa-05_assessment_sticky",
    "description": "Bookimed can help coordinate an assessment. Provider listings do not guarantee availability through Bookimed or an individual treatment price."
  },
  "date_label": "Created",
  "evidence_date": "2026-10-08",
  "relations": [
    {
      "label": "Paroxysmal AF after medication fails",
      "url": "https://hub.bookimed.com/pulsed-field-ablation/paroxysmal-af-after-medication-fails/",
      "group": "Understanding AF and treatment choice"
    },
    {
      "label": "Pulsed field ablation: how treatment works",
      "url": "https://hub.bookimed.com/pulsed-field-ablation/",
      "group": "Understanding AF and treatment choice"
    },
    {
      "label": "PFA compared with radiofrequency and cryoballoon",
      "url": "https://hub.bookimed.com/pulsed-field-ablation/pfa-vs-radiofrequency-cryoballoon/",
      "group": "Understanding AF and treatment choice"
    },
    {
      "label": "PFA for persistent and paroxysmal AF",
      "url": "https://hub.bookimed.com/pulsed-field-ablation/pfa-persistent-vs-paroxysmal-af/",
      "group": "Outcomes and care"
    },
    {
      "label": "PFA safety and serious complications",
      "url": "https://hub.bookimed.com/pulsed-field-ablation/pfa-safety-serious-complications/",
      "group": "Outcomes and care"
    },
    {
      "label": "After PFA: monitoring, medicines and travel",
      "url": "https://hub.bookimed.com/pulsed-field-ablation/after-pfa-monitoring-medicines-travel/",
      "group": "Outcomes and care"
    },
    {
      "label": "PFA costs and an individual estimate",
      "url": "https://hub.bookimed.com/pulsed-field-ablation/pfa-cost-individual-estimate/",
      "group": "Planning and providers"
    },
    {
      "label": "Choosing a PFA centre",
      "url": "https://hub.bookimed.com/pulsed-field-ablation/choosing-pfa-centre/",
      "group": "Planning and providers"
    },
    {
      "label": "Cleveland Clinic PFA programme",
      "url": "https://hub.bookimed.com/pulsed-field-ablation/cleveland-clinic-pfa-programme/",
      "group": "Planning and providers"
    },
    {
      "label": "Dr Oliver Segal: PFA specialist",
      "url": "https://hub.bookimed.com/pulsed-field-ablation/oliver-segal-pfa-specialist/",
      "group": "Planning and providers"
    }
  ],
  "footer_text": "This information supports, but does not replace, an individual electrophysiology assessment. Do not change prescribed treatment without your care team.",
  "topic_navigation": {
    "id": "pfa-topic-navigation",
    "heading": "Explore AF and pulsed field ablation",
    "groups": [
      {
        "label": "Understanding AF and treatment choice",
        "links": [
          {
            "slug": "paroxysmal-af-after-medication-fails",
            "label": "Paroxysmal AF after medication fails"
          },
          {
            "slug": "pulsed-field-ablation-guide",
            "label": "Pulsed field ablation: how treatment works"
          },
          {
            "slug": "pfa-vs-radiofrequency-cryoballoon",
            "label": "PFA compared with radiofrequency and cryoballoon"
          }
        ]
      },
      {
        "label": "Outcomes and care",
        "links": [
          {
            "slug": "pfa-persistent-vs-paroxysmal-af",
            "label": "PFA for persistent and paroxysmal AF"
          },
          {
            "slug": "pfa-safety-serious-complications",
            "label": "PFA safety and serious complications"
          },
          {
            "slug": "after-pfa-monitoring-medicines-travel",
            "label": "After PFA: monitoring, medicines and travel"
          }
        ]
      },
      {
        "label": "Planning and providers",
        "links": [
          {
            "slug": "pfa-cost-individual-estimate",
            "label": "PFA costs and an individual estimate"
          },
          {
            "slug": "choosing-pfa-centre",
            "label": "Choosing a PFA centre"
          },
          {
            "slug": "cleveland-clinic-pfa-programme",
            "label": "Cleveland Clinic PFA programme"
          },
          {
            "slug": "oliver-segal-pfa-specialist",
            "label": "Dr Oliver Segal: PFA specialist"
          }
        ]
      }
    ]
  },
  "section": {
    "url": "https://hub.bookimed.com/pulsed-field-ablation/",
    "name": "Pulsed field ablation guide",
    "wordpress_parent_id": 10796
  }
}